Capricor Therapeutics, Inc. stock is up 15.62% since 30 days ago. The next earnings date is May 9, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 50% of the previous 21 March’s closed higher than February.
Capricor Therapeutics, Inc. focuses on the development of transformative cell and exosome-based therapeutics. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, has completed phase III clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD) The company also develops CAP-2003 that is in pre-clinical development for the. treatment of trauma related injuries and conditions; and two vaccine candidates, which are in development stage for the potential prevention of COVID-19.
Unlock Exclusive Market Insights! Receive timely updates on market developments. Sign up & stay informed!